Bristol-Myers, J&J Ink Immunotherapy Research Collaboration – Yahoo Finance
Nasdaq |
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
Yahoo Finance We remind investors that Bristol-Myers and Janssen entered into a clinical research collaboration in Jul 2016 to evaluate Opdivo and the latter's live attenuated double-deleted Listerial monocytogenes cancer immunotherapy, expressing mesothelin and … Bristol-Myers Squibb Announces Immunotherapy Clinical It Was CheckMate for Bristol-Myers Squibb Company in 2016 |
